Intellipharmaceutics International Inc. (IPCI) PT Set at $8.00 by Brean Capital
Intellipharmaceutics International Inc. (NASDAQ:IPCI) has been given a $8.00 price target by investment analysts at Brean Capital in a report issued on Monday. The brokerage presently has a a “buy” rating on the stock. Brean Capital’s price target would suggest a potential upside of 181.69% from the stock’s previous close.
Several other research firms have also issued reports on IPCI. Zacks Investment Research upgraded shares of Intellipharmaceutics International from a “hold” rating to a “buy” rating and set a $1.50 target price for the company in a report on Wednesday, June 15th. Maxim Group set a $6.00 target price on shares of Intellipharmaceutics International and gave the stock a “buy” rating in a report on Thursday, October 6th.
Intellipharmaceutics International (NASDAQ:IPCI) traded down 7.39% during midday trading on Monday, reaching $2.63. 859,336 shares of the company traded hands. Intellipharmaceutics International has a one year low of $1.41 and a one year high of $3.19. The stock’s market capitalization is $75.60 million. The company has a 50 day moving average price of $1.97 and a 200-day moving average price of $1.84.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/11/intellipharmaceutics-international-inc-ipci-pt-set-at-8-00-by-brean-capital.html
Intellipharmaceutics International (NASDAQ:IPCI) last released its quarterly earnings data on Wednesday, July 13th. The company reported ($0.08) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.09) by $0.01. Intellipharmaceutics International had a negative net margin of 325.20% and a negative return on equity of 832.00%. Analysts forecast that Intellipharmaceutics International will post ($0.28) EPS for the current fiscal year.
An institutional investor recently bought a new position in Intellipharmaceutics International stock. Atria Investments LLC purchased a new stake in Intellipharmaceutics International Inc. (NASDAQ:IPCI) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 67,727 shares of the company’s stock, valued at approximately $106,000. Atria Investments LLC owned about 0.27% of Intellipharmaceutics International as of its most recent SEC filing. 1.30% of the stock is owned by hedge funds and other institutional investors.
Intellipharmaceutics International Company Profile
Intellipharmaceutics International Inc is a pharmaceutical company specializing in the research, development and manufacture of controlled-release and targeted-release oral solid dosage drugs. The Company’s Hypermatrix technology is a multidimensional controlled-release drug delivery platform that is applied to the development of a range of existing and new pharmaceuticals.
Receive News & Ratings for Intellipharmaceutics International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellipharmaceutics International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.